Chemours Co

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No. )

THE CHEMOURS COMPANY

​

(Name of Registrant as Specified in its Charter)

​

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

On behalf of the Board of Directors, thank you for your continued trust and investment in Chemours. I’ve had the privilege of serving on Chemours’ Board since the company’s inception in 2015. Today, it is an honor to address you for the first time as Chair of the Board and share our progress over the past year.

NEW BOARD STRUCTURE FOR LONG-TERM SUCCESS

In September 2025, I was appointed Chair of the Board and Alister Cowan was named Lead Independent Director of the Board, succeeding our former Chair, Dawn Farrell, who was tapped for a high-level position with the Canadian government. In this new structure, I lead the Board, set the agenda, and drive its focus on long-term strategy and shareholder value creation. I am the liaison between our CEO, Denise Dignam, and the independent directors. Working closely with Mr. Cowan, I oversee shareholder engagement and represent the Board in communications with shareholders. Mr. Cowan brings deep financial expertise and works hand in hand with me on Board activities related to overall financial performance. He leads Board discussions regarding capital allocation, financial performance, risk topics and corporate development activities. Together alongside our fellow directors, we support our CEO and the full management team as they execute Chemours’ Pathway to Thrive (“PTT”) strategy.

On behalf of the Board, I would like to express our sincere gratitude to our former Chair, Dawn Farrell, for her outstanding leadership and contributions to Chemours since its founding. Mrs. Farrell’s guidance and dedication helped position Chemours for the future, and I am proud to continue building on the foundation she established.

In 2025, we continued to strengthen our Board’s financial depth and capital markets expertise with additions of George R. Brokaw and Courtney R. Mather who were elected as new directors at last year’s Annual Meeting. Chaired by Mr. Cowan, the Audit, Risk and Finance Committee (previously the Audit Committee) expanded its oversight in 2025 and has deepened its focus on capital allocation, treasury, finance, liquidity and investment matters. Demonstrating the depth of our Board leadership, two experienced new committee chairs were appointed in 2025: Sean D. Keohane took over for me as Chair of the Nominating and Corporate Governance Committee, and Livingston L. (Tony) Satterthwaite succeeded Mr. Keohane as Chair of the Compensation and Leadership Development Committee.

Following our multi-year refresh of our Board, I am confident we have the right mix of skills, experience, and industry insight to support Chemours’ long-term growth and strategic priorities.

DISCIPLINED EXECUTION AGAINST PATHWAY TO THRIVE STRATEGY IN 2025

I’m extremely proud of the progress Ms. Dignam and the Chemours management team delivered in 2025, especially in the face of challenging market dynamics. They remained focused on advancing actions within their control and executed against the PTT strategy to strengthen the Company’s position and support more consistent performance and value creation over time.

Under Ms. Dignam’s leadership, management strengthened its balance sheet, sharpened its focus on cash generation and capital discipline, simplified its operating footprint, improved its operational rigor, resolved legacy liabilities, and advocated for the essentiality of Chemours’ chemistries. At the same time, management made deliberate progress in positioning Chemours for the future by advancing growth opportunities in high potential sectors — including data centers, semiconductors, and low global warming refrigerants — where Chemours’ differentiated technologies and expertise are positioned to win.

The Board is encouraged by the momentum built in Ms. Dignam’s first full year as CEO and is confident in management’s ability to continue translating these actions into durable shareholder value.

LEADING RESPONSIBLY

Leading responsibly remains central to the Board’s oversight and Chemours’ long-term success. Over the past year, Chemours continued to demonstrate industry leadership in responsible manufacturing, foster a strong culture of accountability and ethics, and enhance its approach to identifying and managing enterprise risks.

Following the launch of our refreshed values in 2024, management remained focused on strengthening our Speak Up culture by encouraging employees to raise concerns and engage in open dialogue without fear of retaliation.

Chemours also continued to strengthen how enterprise risks are identified, assessed, and managed across the Company. Risk discussions are integrated with the Company’s strategic planning and ongoing business reviews, supporting informed decision-making aligned with the PTT strategy.

In 2025, Chemours refreshed its 2030 Corporate Responsibility Commitment (“CRC”) goals, more closely aligning them with Chemours’ Trusted Chemistry vision, strategic priorities, and evolving stakeholder expectations — and continued to advance progress against the individual goals throughout the year. Environmental, health, and safety performance remains foundational to how we operate. Through sustained focus on responsible manufacturing, we are protecting our privilege to operate and building a stronger Chemours.

COMMITTED TO SHAREHOLDER ENGAGEMENT AND RESPONSIVENESS

The Board values the perspectives of our shareholders and maintains an active dialogue on governance, stewardship, and long-term priorities. In 2025, members of the Board engaged with shareholders to discuss stewardship and governance-related matters. By engaging regularly, we broaden our perspective and ensure we remain responsive to the long-term interests of our shareholders while advancing Chemours’ vision for sustainable growth.

LOOKING AHEAD

Chemours enters 2026 with a clear strategy, industry leading businesses, a strengthened leadership team, and a Board deeply committed to long-term value creation. Our PTT framework is more than a plan — it’s a roadmap for sustainable growth, operational excellence, and responsible leadership. With the right talent, governance, and strategic focus in place, we are confident in Chemours’ ability to deliver strong performance and create enduring shareholder value.

On behalf of the Board, I invite you to attend our 2026 Annual Meeting of Shareholders on Friday, April 24, 2026 at 10:00 am ET. The attached Notice of the 2026 Annual Meeting of Shareholders and Proxy Statement contains information about the business to be conducted at the Annual Meeting. We look forward to continuing the dialogue with you, our shareholders, and thank you for your ongoing support. Together, we will continue to build a stronger Chemours — one that thrives for decades to come.

Sincerely,

Mary B. Cranston

Chair of the Board

ABOUT CHEMOURS

OUR COMPANY

CHEMOURS DELIVERS TRUSTED CHEMISTRY THAT IS ESSENTIAL TO THE WORLD

The Chemours Company is a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. Our world-class product portfolio and unmatched expertise in chemistry brings everyday convenience to virtually everything people touch in their daily lives, making our products and the solutions they enable both vital and essential.

Science and technology are the cornerstones of our innovation, with a focus on key markets, including clean energy, advanced electronics and high-performance computing, sustainable cooling, high-quality paints, coatings and laminates. Our customer base includes a diverse set of companies, many of which are leaders in their respective industries.

We are committed to creating value for our customers and stakeholders around the world through innovative and sustainable solutions, using chemistry to help people live better and communities thrive. Our talented and deeply knowledgeable people move our business forward and are Chemours’ greatest advantage in achieving the best outcomes for our business, shareholders and communities.

INDUSTRY LEADING BUSINESSES

OUR CORPORATE STRATEGY

Chemours’ business strategy, Pathway to Thrive, capitalizes on the fundamental strengths of our three business segments — Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials — as well as our talented people and competitive differentiators in each segment. Under Pathway to Thrive, we have a clear framework and actionable steps to create near- and long-term value centered around four pillars: Operational Excellence, Enabling Growth, Portfolio Management, and Strengthening the Long Term. Each of these pillars is rooted in our foundation of balanced and disciplined capital allocation. As we drive our strategy and operate our business, we do so guided by our values and our vision to deliver trusted chemistry. Together, our values, vision, and strategy guide and reflect the fundamental strengths of our businesses and our incredible talent.

The Annual Meeting of Shareholders for The Chemours Company (the “Company”) will be held virtually on April 24, 2026, at 10:00 a.m. Eastern Time (including any adjournments or postponements) for the following purposes:

Only shareholders of record at the close of business on March 2, 2026 are entitled to notice of, and to vote at, the Annual Meeting, and any adjournments or postponements of the Annual Meeting.

By Order of the Board of Directors

KRISTINE M. WELLMAN

Senior Vice President, General Counsel &

Corporate Secretary

March 10, 2026

YOUR VOTE IS IMPORTANT. Even if you plan to attend the Annual Meeting, we still encourage you to submit your proxy via Internet, telephone or mail prior to the meeting. If you later choose to revoke your proxy or change your vote, you may do so by following the procedures described under “Can I revoke a proxy?” and “Can I change my vote after I have delivered my proxy?” in the “General Information About the Meeting” section of the attached Proxy Statement.